Key result
The 2BT-pIgG-Fc recombinant vaccine induced FMDV-specific antibodies with a percentage inhibition of 90.43%, comparable to the 81.75% seen with a commercial vaccine.
Why the study?
Inactivated foot-and-mouth disease vaccines have drawbacks including high production costs, biological safety risks, and the requirement for biosafety level 3 facilities to handle live virus.
Does a recombinant protein vaccine (2BT-pIgG-Fc) induce FMDV-specific and neutralizing antibodies comparable to commercial inactivated vaccines in guinea pigs and pigs?
Does a recombinant protein vaccine (2BT-pIgG-Fc) induce FMDV-specific and neutralizing antibodies comparable to commercial inactivated vaccines in guinea pigs and pigs?
Mean Difference: 8.68
Absolute Event Rate: 90.43% vs 81.75%
p-value: p=ns
A novel recombinant protein vaccine (2BT-pIgG-Fc) demonstrated FMDV-specific antibody production and neutralization efficiency similar to commercial inactivated vaccines in pigs, offering a potential safer and cost-effective alternative.
Recombinant FMDV vaccine elicits comparable antibodies; hypothesis-generating for veterinary candidates and leaves open protective efficacy trials.
The inactivated vaccine is effective in controlling foot-and-mouth disease (FMD), but it has drawbacks such as the need for a biosafety level 3 laboratory facility to handle live foot-and-mouth disease virus (FMDV), high production costs, and biological safety risks. In response to these challenges, we developed a new recombinant protein vaccine (2BT-pIgG-Fc) containing porcine IgG-Fc to enhance protein stability in the body. This vaccine incorporates two-repeat B-cell and one-single T-cell epitope derived from O/Jincheon/SKR/2014. Our study confirmed that 2BT-pIgG-Fc and a commercial FMDV vaccine induced FMDV-specific antibodies in guinea pigs at 28 days post-vaccination. The percentage inhibition (PI) value of 2BT-pIgG-Fc was 90.43%, and the commercial FMDV vaccine was 81.75%. The PI value of 2BT-pIgG-Fc was 8.68% higher than that of commercial FMDV vaccine. In pigs, the primary target animals for FMDV, all five individuals produced FMDV-specific antibodies 42 days after vaccination with 2BT-pIgG-Fc. Furthermore, serum from 2BT-pIgG-Fc-vaccinated pigs exhibited neutralizing ability against FMDV infection. Intriguingly, the 2BT-pIgG-Fc recombinant demonstrated FMDV-specific antibody production rates and neutralization efficiency similar to commercial inactivated vaccines. This study illustrates the potential to enhance vaccine efficacy by strategically combining well-known antigenic domains in the development of recombinant protein-based vaccines.
No takes yet. Share an insight, caveat, or question.
Song et al. (2024) studied Foot-and-Mouth Disease (n=37). 2BT-pIgG-Fc recombinant protein vaccine vs. Commercial FMDV vaccine was evaluated on Percentage inhibition (PI) of FMDV-specific antibodies at 28 days post-vaccination in guinea pigs (8.68% higher PI, p=ns). The 2BT-pIgG-Fc recombinant vaccine induced FMDV-specific antibodies with a percentage inhibition of 90.43%, comparable to the 81.75% seen with a commercial vaccine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: